Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.46 |
| ▸ | DRD3 | P35462 | 12/20 | 0.46 |
| ▸ | DRD4 | P21917 | 8/20 | 0.46 |
| ▸ | HTR1A | P08908 | 6/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850245 | 0.99 | DRD2 (0.46) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL17486586 | 0.93 | DRD2 (0.43) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL17354298 | 0.90 | DRD2 (0.41) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL13973 | 0.89 | TP53 (0.41) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL13791 | 0.88 | TP53 (0.40) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL13919 | 0.87 | CCR2 (0.43) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL14146 | 0.86 | CCR2 (0.44) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL17354254 | 0.85 | KMT2A (0.48) | DRD2DRD3HTR1AADRA1DADRA1A | |
| SCHEMBL14011 | 0.85 | DRD2 (0.40) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL13638 | 0.84 | DRD2 (0.40) | DRD2DRD3DRD4HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011047323-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090326-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | DRD2 2468/4885DRD3 1527/4885DRD4 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.